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A variety of genetic alterations have been identified in invasive
breast cancer. The most frequent aberrations include amplifica-
tions of oncogenes, mutations in p53 and loss of heterozygosity
(LOH) at a number of other but still putative tumour suppressor
genes. The multitude of genetic changes so far has precluded the
construction of a molecular progression model comparable to that
for colorectal development (Vogelstein et al, 1988). It seems
likely, therefore, that breast cancer not only clinico-pathologically,
but also genetically is a heterogeneous disease. The clinico-patho-
logical heterogeneity is already manifest in its histologically
recognizable precursor lesion, ductal carcinoma in situ (DCIS).
DCIS represents a proliferation of malignant cells within the ducts
and lobules of the breast. Recently, several histological classifica-
tions have been proposed (Tavassolli et al, 1992; Holland et al,
1994; Silverstein et al, 1995; Scott et al, 1997). In all of these clas-
sifications DCIS is divided primarily on the basis of nuclear grade
and/or necrosis, while architecture is given secondary considera-
tion. The classifications differ to some degree, but all subdivide
DCIS into three main subtypes: well-, intermediately and poorly
differentiated. The relevance of implementation of biological
markers to facilitate the histological classification of DCIS is
supported by several studies (Bobrow et al, 1994; Zafrani et al,
1994; Mack et al, 1997). These studies have shown that poorly
differentiated DCIS predominantly lack the oestrogen (ER) and
progesterone receptor (PR), have a high proliferative rate, exhibit
aneuploidy and c-erbB2/neu and p53 overexpression. In contrast,
well-differentiated DCIS are often ER- and PR-positive, have a
low proliferative rate and rarely show c-erbB2/neu and p53 over-
expression.
In DCIS, three allelotyping studies have previously identified
chromosomal loci with common allelic loss in DCIS. In all studies
it was found that LOH on 16q, 17p and 17q are the most frequently
found alterations in DCIS (Aldaz et al, 1995; Radford et al, 1995;
Fujii et al, 1996).
Gene amplifications in DCIS have been studied by Southern
blot analysis, fluorescent in situ hybridization (FISH), bright field
in situ hybridization (BRISH) or comparative genomic hybridiza-
tion (CGH). FISH revealed amplification of c-erbB2/neu in 30%
of the DCIS cases (Murphy et al, 1995; Coene et al, 1997). By
Southern blot analysis and BRISH, cyclin D1 gene amplification
was found present in 12% of DCIS (Vos et al, submitted) and by
FISH in 18% of DCIS (Simpson et al, 1997). Two CGH studies
were done recently for nine and five cases of DCIS respectively
(James et al, 1997; Kuukasjarvi et al, 1997). The most frequently
found alterations were gains of 1q, 6q, 8q, 17q, 19q, 20p, 20q and
Xq as well as losses of 13q, 14q, 16q, 17p and 22q.
In the present comprehensive study we aimed to obtain an
insight of the genetic changes occurring in the histologically
different types of DCIS and to explore whether specific genetic
alterations are associated with specific histologic types of DCIS.
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Summary We analysed the involvement of known and putative tumour suppressor- and oncogene loci in ductal carcinoma in situ (DCIS) by
microsatellite analysis (LOH), Southern blotting and comparative genomic hybridization (CGH). A total of 78 pure DCIS cases, classified
histologically as well, intermediately and poorly differentiated, were examined for LOH with 76 markers dispersed along all chromosome
arms. LOH on chromosome 17 was more frequent in poorly differentiated DCIS (70%) compared to well-differentiated DCIS (17%), whereas
loss on chromosome 16 was associated with well- and intermediately differentiated DCIS (66%). For a subset we have done Southern blot-
and CGH analysis. C-erbB2/neu was amplified in 30% of poorly differentiated DCIS. No amplification was found of c-myc, mdm2, bek, flg and
the epidermal growth factor (EGF)-receptor. By CGH, most frequent alterations in poorly differentiated DCIS were gains on 8q and 17q22–24
and deletion on 17p, whereas in well-differentiated DCIS amplification on chromosome 1q and deletion on 16q were found. In conclusion, our
data indicates that inactivation of a yet unknown tumour suppressor gene on chromosome 16q is implicated in the development of most well
and intermediately differentiated DCIS whereas amplification and inactivation of various genes on chromosome 17 are implicated in the
development of poorly differentiated DCIS. Furthermore these data show that there is a genetic basis for the classification of DCIS in a well
and poorly differentiated type and support the evidence of different genetic routes to develop a specific type of carcinoma in situ of the breast.
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MATERIALS AND METHODS
Loss of heterozygosity
Selection of tumour material and DNA isolation
For the LOH analysis we obtained 78 cases of pure DCIS from the
archives of the Departments of Pathology of the Netherlands
Cancer Institute (NCI), Leiden University Medical Center
(LUMC) and University Hospital Nijmegen. The cases were
selected on the basis of histological type and classified as well-
differentiated (n = 26), intermediately differentiated (n = 17) and
poorly differentiated (n = 35) according to the classification
proposed by Holland et al (1994). Briefly, the histologic classifica-
tion of DCIS can be summarized as follows: poorly differentiated
DCIS is composed of cells with pleomorphic nuclei varying in size
and shape with irregular contours, coarse chromatin and promi-
nent nuclei. Frequent mitosis and extensive ‘comedo’ necrosis
centrally in ducts are usually present. The cells have no tendency
towards polarization resulting in a solid growth pattern.
Intermediately differentiated DCIS is characterized by cells with
moderately pleomorphic, slightly larger nuclei than well differen-
tiated DCIS. The cells show a definite tendency towards polariza-
tion, i.e. an orientation of the apical side towards a lumen,
resulting in trabecular or cribriform pattern. Well-differentiated
DCIS is characterized by cells with monomorphic, equally sized
nuclei with smooth nuclear membrane, uniform, fine chromatin
and inconspicuous nuclei. Architectural differentiation is
evidenced by pronounced polarization resulting in cribriform,
micropapillary and clinging growth patterns. The mitotic rate is
low and necrosis is hardly ever seen. In Figure 1, typical examples
of well-, intermediately and poorly differentiated DCIS are shown.
All cases were histologically classified by two pathologists (JL
and MvV) independently. In case of disagreement, agreement was
reached by looking at the slide together. To exclude invasion, the
lesion was fully embedded or at least eight sections were taken.
For each case tissue blocks containing at least 20 ducts with
DCIS were selected and four sections of 25 mm were deparaf-
finized, stained with haematoxylin and eosin (H&E) and micro-
dissected under an inverted microscope using a 22 gauge needle.
All in situ foci were selectively dissected, pooled and used for
DNA isolation. Paraffin-embedded, tumour-negative lymph nodes
or normal breast tissue isolated from a different tissue-block, were
used to provide constitutional DNA from each patient. Tissue
was digested in 500 ml DNA extraction buffer (100 mM sodium
chloride, 10 mM Tris–HCl (pH = 8.0), 25 mM EDTA (pH = 8.0)
and 0.5% sodium dodecyl sulphate (SDS)) and incubated at
Table 1 Polymorphic markers and the percentage of LOH observed in DCIS allelotyping (het=heterozygosity frequency based on CEPH data)
Chromosome Marker Het. LOH % Chromosome Marker Het. LOH %
1p21 AMY2B 0.68 0/35 13q14.1–14.3 D13S153 0.82 4/34 11.8
1q21–23 APOA2 0.74 0/35 13q12.3 D13S260 0.78 2/38 5.3
1q21–23 D1S104 0.76 2/47 4.2 13q11 D13S175 0.77 4/52 7.7
1q32–q44 D1S103 0.88 1/51 1.9 13q12.1 D13S290 0.46 2/29 6.9
2p25–p24 TPO 0.67 0/32 13q D13S321 0.78 3/38 7.9
2q33 CTLA4 0.92 0/48 14q11.2 D14S50 0.77 0/41
3p24.4–p22 D3S11 0.93 5/61 8.2 14q32.1-qter D14S51 0.77 0/43
3p24.2–p22 D3S1768 0.73 3/45 6.7 15pter-qter D15S1232 0.83 0/25
3p22–p14 D3S2456 0.81 7/55 12.7 15q25-qter D15S87 0.87 0/47
3p24 D3S1300 0.83 4/31 12.9 16p13.3 HBAP1 0.76 6/45 13.3
3pter–p24 D3S1244 0.62 2/28 7.1 16q21 D16S265 0.73 9/33 27.2
3q26–q26.3 GLUT2 0.91 5/45 11.1 16q21 D16S503 0.81 8/28 28.5
3q27–q28 D3S196 0.67 6/58 10.3 16q22.1 D16S512 0.76 16/48 33.3
4p21.1–p14 D4S174 0.92 0/53 16q22.1-qter D16S2624 0.85 21/50 42.0
5p D5S392 0.92 0/57 16q22.1-qter D16S752 0.92 25/59 42.3
5q11.1–q13.3 D5S107 0.82 0/49 16q23.2 D16S266 0.60 9/31 29.0
6p22 D6S105 0.87 0/58 16q24.2–q24.3 D16S1320 20/53 37.7
6p24–p22 D6S1279 0.86 0/52 16q24.3 D16S305 0.82 9/33 27.2
6p24–P22 D6S1955 0.75 0/51 17pter-qter D17S969 0.72 16/51 31.3
6q D6S1010 0.75 3/38 7.9 17pter-qter D17S1537 0.78 15/37 40.5
6q13–q21.1 D6S251 0.78 2/52 3.8 17p13.3 D17S513 0.89 10/29 34.4
6q26–q27 IGFR2 0.42 3/25 12.0 17p13.1 TP53 19/61 31.1
7p15–p21 D7S488 0.85 0/52 17p12 D17S520 0.77 5/18 27.7
7q31-qter D7S550 0.83 0/49 17q12–q22 D17S579 0.87 14/50 28.0
8p22–p12 D8S1130 0.93 14/64 21.8 17q21 D17S855 0.82 15/48 31.2
8p21–p12 GATA119CO6 8/51 15.6 17q23 D17S588 0.85 16/45 35.5
9p21 D9S43 0.83 0/51 18 D18S46 0.80 3/52 5.8
9q D9S53 0.87 0/57 18q11 D18S34 0.81 3/46 6.5
10pter–p11.2 D10S89 0.80 0/48 19p13.3 D19S177 0.82 0/36
10q11.2-qter D10S109 0.71 0/39 19q12–q13.2 APOC2 0.80 0/42
11pter–p11.2 D11S875 0.90 2/59 3.4 20p12 D20S66 0.78 0/41
11p15 D11S1999 0.76 0/52 20q13.3 CSTP1 0.61 0/24
11q D11S897 0.84 8/54 14.8 21q22.3 D21S156 0.92 0/48
11q22 D11S35 0.88 8/57 14.0 22q13 CYP2D 0.80 4/57 7.0
11q23.3-qter D11S836 0.70 3/42 7.1 Xp22.3 Kallman 0.61 0/39
12pter–p11.2 D12S59 0.81 0/45 Xq21.1–q23 DXS454 0.75 1/52 1.9
12q23-qter PLA2 0.73 0/38
12q22-qter D12S79 0.96 0/60
13q12.1 D13S289 0.74 2/27 7.41412 CBJ Vos et al
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56°C for 72 h. Each day, 15 ml proteinase K (10 mg ml–1) was
added. Subsequently phenol–chloroform extraction was performed
followed by an ethanol precipitation in the presence of 2 ml
glycogen (20 mg ml–1) and 7.5 M NH4Ac (Isola et al, 1994). The
DNA was diluted in 100–200 ml 10 mM Tris–HCl (pH = 7.6)/
0.1 mM EDTA.
Allelotyping and microsatellite markers
DNA from tumour cells and from normal cells was analysed using
the polymerase chain reaction (PCR) with primers for di-, tri- or
tetranucleotide repeats of known chromosomal location. PCR was
performed in a 96-well microtitreplate in a 12-ml reaction volume
containing 1.5 ml DNA, 1.2 ml 10 ´ SuperTaq buffer (HT
Biotechnology), 0.1 mg ml–1 bovine serum albumin (BSA),
0.2 mM dATP, dGTP and dTTP, 2.5 mM dCTP), 5 pmol of each
primer, 1.0 mCi a-32PdCTP, 0.06 U SuperTaq (HT-Biotechnology)
and water. The PCR conditions were 5 min 95°C followed by
33 cycles of 1 min 95°C, 1 min 55°C and 1.5 min 72°C. The pro-
ducts were electrophoresed on 6% polyacrylamide, 8 M urea
sequencing gels at 70 W constant power for 1–2 h. The gels were
dried and exposed to X-ray film for 4–72 h.
Microsatellite analysis was performed at 76 loci covering all
chromosome arms. Many of the loci were chosen because they are
located at or near regions found to be involved in breast cancer.
Loci studied by microsatellite analysis are listed in Table 1. All
markers used are described in the Genome Database (GDB).
Allelic loss was defined as loss of one allele in DCIS DNA
compared to the constitutional DNA as determined by visual
inspection of the autoradiograph, which was clear in most cases
due to the enrichment for tumour cells. However, when a residual
signal was seen, due to contaminating normal tissue or tumour
heterogeneity, quantitative analysis on a Phosphor Imager
(Molecular Dynamics) was used to determine the allelic imbalance
factor (the ratio of allele1/allele2 of the control DNA and
allele1/allele2 of the tumour DNA). An imbalance factor over 1.8
was considered as LOH. To confirm the results, PCR reactions
were repeated for all cases showing LOH.
Table 2 Association of histologic type of DCIS with loss of heterozygosity on chromosome 16 and 17 in respectively 70 and 72 cases of DCIS (P-values given
were calculated using the c2 test)
LOH Retention % LOH LOH LOH Retention %
16q 16q LOH whole chrom. 17 17p 17q 17 LOH
Well-differentiated DCIS 16 7 70 0 1 3 19 17
Intermediately differentiated 10 6 63 1 3 6 6 63
DCIS
Poorly differentiated DCIS 12 19 39 6 11 6 10 70
P-value: 0.037 P-value: 0.0002
A
B
C
Figure 1 Examples of the histologic classification of DCIS. (A): well
differentiated DCIS, (B): intermediately differentiated DCIS, (C): poorly
differentiated DCISGenetic alterations in DCIS 1413
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Gene amplification
Southern blot analysis
From tissuebanks of the NCI and LUMC 80 samples of freshly
frozen samples were collected. H&E sections of the frozen
samples were examined by light microscopy and the tumour
percentage was estimated. Only 32 specimens, which is a subset of
the samples used for LOH analysis, met the requirement of 30% or
more tumour cells and were classified as 20 poorly, six intermedi-
ately and six well-differentiated DCIS.
High molecular weight DNA was isolated by standard methods
(Sambrook et al, 1989). In addition, the following cell lines and
tissues were used as controls: two breast carcinoma cell lines,
MDA134 and SKBR3 (c-myc and c-erbB2/neu gene amplifica-
tion) and a cell line derived from normal mammary tissue
(HBL100) and placenta. DNA was digested with the restriction
endonuclease EcoRI (Pharmacia, Uppsala, Sweden) using buffers
recommended by the suppliers. The digested DNA was size-frac-
tionated overnight by gel electrophoresis on a 0.8% agarose gel in
1 ´ TAE, denatured and transferred with 1 M sodium chloride–
0.4 M sodium hydroxide onto nylon membranes (Hybond N+,
Amersham, UK). After transfer the filters were neutralized in
0.5 M Tris–HCl–1 M sodium chloride (pH = 7.2) buffer, dried
and baked at 80°C for 2 h.
Hybridization
Filters were pre-hybridized for 0.5 h at 65°C in hybridization mix
(1 M Na2HPO4–1 M NaH2PO (pH = 7.2)/7% SDS–0.5 M EDTA).
The pSV2erbB2/neu construct which contains the complete cDNA
of c-erbB2/neu was kindly provided by Dr Yamamoto (Yamamoto
et al, 1986). The EGF receptor cDNA clone was kindly provided
by Dr Ullrich (Ullrich et al, 1984). The c-myc probe was derived
from the pHM-1 clone containing the complete human c-myc gene
(Adams et al, 1985). From this clone a 400 bp PstI/PstI fragment
of exon II was used for hybridization. The MDM2 probe was a
585 bp reverse transcription PCR (RT-PCR) fragment spanning
nucleotides 650–1214 of the published cDNA sequence (Oliner
et al, 1992; Marchetti et al, 1995). The bek and flg probes were
kindly provided by Dr Theillet (Adnane et al, 1991). All probes
were radiolabelled with 20 mCi of [a-32P]dCTP (> 3000 Ci
mmol–1, Amersham, UK) using a random-primed labelling kit
(Pharmacia, Upsalla, Sweden). After at least 17 h of hybridization,
filters were washed at 65°C to a final stringency of 0.1 ´ standard
saline citrate (SSC) 0.1% SDS. The filters were exposed to Kodak
Xomat AR films with DuPont Cronex Lightning Plus screens for
2–5 days at –70°C. The degree of amplification was determined by
visual inspection comparing signal intensity of the various probes
with probes located in non-amplified regions at the same chromo-
some arm (chromosome 8 (thyroglobulin), 12 (D12S2) and 17
(D17Z1)). All probes are described in the GDB. The same filters
were repeatedly hybridized.
CGH analysis
Five well-differentiated DCIS and ten poorly differentiated DCIS
were tested by CGH. Tumour DNA (test DNA) was extracted
Table 3 Number of loci involved in LOH compared to histological classification of DCIS (P-value was calculated using the c2 test)
DCIS
Well-differentiated Intermediately Poorly
differentiated differentiated
No LOH 7 6 10
1–3 chromosomal loci involved 16 10 14
> 3 chromosomal loci involved 7
P-value:0.004
Table 4 Summary of chromosomal regions involved in 15 DCIS cases detected by CGH
Tumour number Copy gain regions Deleted regions
Poorly differentiated
BT1253 17q22–24, 8q23–24 17p, 8p21–23
BT1251 17q22–24
BT1265 1q, 8q, 16p, 17q12, 17q22–24 11q, 16q, 17p, 22q
BT1204 chrom. 5, 8q, 12q13–22, 20q 11q23–25, 17p, 22q13
BT1255 17q12, 17q22–24, 6p12
BT1268 chrom. X 17p, 5q23, 6q21–22
BT1213 11q13, 12q14–15, 5q 17p
BT1222 1q, 6p23–24 17p, 9q34, 16q
BT1211 4q, Xq21, 2q 17p, 16q
BT1224 8q, 11q13, 12q14–15, 17q12, 20q 8p
Well-differentiated
BT1290 1q, 16p 16q22–24, 22q
BT1445 1q, 3p24, 11q13, 19q 3p12–14, 11q23–25
BT1230 chrom5, 7, 12, 19, 20 and X
BT1285 8p12–22, 16q, 19
BT1238 No changes No changes1414 CBJ Vos et al
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either from frozen material (BT1253 and BT1290) or from
microdissected, paraffin-embedded material (all other cases).
DNA from uncultured peripheral blood from a healthy female was
used as reference DNA. The CGH procedure was based on the
protocol described by Kallioniemi (Kallioniemi et al, 1992, 1994),
with a few modifications. Briefly, test DNA was direct-labelled
with lissamine-dUTP (NEN Life Sciences) and reference DNA
was labelled with fluorescein isothiocyanate (FITC)-dATP
(duPont), both by nick-translation. Two hundred nanograms of
each labelled DNA and 10 mg of COT1 DNA dissolved in 10 ml
hybridization buffer (50% formamide 2 ´ SSC 10% dextran
sulphate) were hybridized to normal male meta-phases and
incubated at 37°C for 4 days. Post-hybridization washes were
performed with 2 ´ SSC at 37°C (3 washes) followed by 0.1 ´ SSC
at 60°C (3 washes). Slides were counterstained with 4,6-
diamidino-2-phenylindole (DAPI) in an antifade solution
(Vectashield, Vector).
Images were acquired with an epifluorescent microscope
(Leica, DM) equipped with three single excitation filters, a multi-
bandpass dichroic mirror, a multi-band pass emission filter (P-1
filter set, Chroma Technology, Brattleborough, VT, USA) and a
cooled CCD camera (Photometrics Inc.). The green, red and blue
images were collected sequentially by changing the excitation
filter. Grey level images (12 bit) were saved using a routine build
up in SCIL-Image (TNO, Delft, The Netherlands) and imple-
mented on a Power Macintosh 8100.
For CGH analysis the QUIPS XL (Downers Grove, IL, USA)
software from Vysis was used. For the profiles, losses of DNA
sequences are defined as chromosomal regions where the mean
green to red fluorescent ratio and its 95% confidence interval is
below 0.9 while gains are defined as chromosomal regions where
this ratio is above 1.1. These thresholds were based on measure-
ments from a series of five controls. The heterochromatic, pericen-
tromeric, and the telomeric regions of the chromosomes, as well as
1p32-pter were excluded from the analysis, because these regions
show variable results in normal controls (Kallioniemi et al, 1994).
RESULTS
Allelotyping
The frequency of LOH for each marker is summarized in Table 1.
Chromosome arms with the highest percentage of LOH are chro-
mosome 3 (13%), 8 (18%), 11 (12%), 13q (12%), 16q (54%), 17p
(21%), 17q (21%), lower percentages were found on chromosome
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Figure 2 Allelotype of DCIS (n=78) compared with invasive breast cancer. The allelotype of DCIS was constructed using our data; the allelotype of invasive
breast cancer was constructed using data from the literature (Devilee et al, 1994)
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Figure 3 Examples of allelic imbalance in DCIS. PCR products are shown
from N (normal) and T (tumour) DNA from individuals with DCIS. The loss of
one allele in the tumour lane is seen in all photographs showing ——>. Allelic
gain is shown as ----- >. (A) Representative microsatellite analysis of well
differentiated DCIS showing LOH with markers on chromosome 16q.
(B) Representative microsatellite analysis of poorly differentiated DCIS
showing LOH with markers on chromosome 17p. (C) Two of the four poorly
differentiated DCIS (BT1255 and BT1253) in which allelic gain occurs with
marker D17S588 (17q23); for the same DCIS cases LOH is shown for
D13S153 (13q12) and D17S855 (17q21)Genetic alterations in DCIS 1415
1q (4%), 6q (9%), 18q (7%), 22q (7%) and Xq (1%). No LOH was
found on chromosome 2, 4, 5, 7, 9, 10, 12, 14, 15, 19, 20 and 21. A
compiled allelotype was made from published studies on cases of
invasive breast carcinoma (Devilee et al, 1994) in order to
compare this with the DCIS allelotype (Figure 2). For all loci
showing LOH in DCIS, LOH was seen in invasive breast cancer.
However, LOH on chromosome arm 1p, 7q, 9q, 15q and 18p was
found in > 20% of invasive carcinomas but not in DCIS suggesting
a possible involvement of tumour suppressor genes in these
regions in progression from DCIS to invasive breast cancer.
LOH on chromosome 16 and 17 were the most frequent find-
ings in DCIS. Representative examples of LOH on chromosome
16 and 17 are shown in Figure 3A and 3B. Table 2 shows the asso-
ciation between histologic type of DCIS and the frequency of
LOH on chromosome 16 and 17. LOH on chromosome 17 was
found in 70% of the poorly differentiated DCIS and in 17% of the
well-differentiated DCIS. In 21% (15/72) of DCIS (predominantly
poorly differentiated) LOH was found restricted to the 17p-arm. In
two poorly differentiated cases, LOH on 17p was restricted to the
region 17p13.3. In all other cases the LOH region included the
17p13.1 region which contains the p53 gene.
Also in 21% (15/72) LOH was found on the 17q-arm. The
common region of overlap was located between marker D17S579
and D17S855. In 10% of the cases (6/72) whole chromosome 17
was afflicted by LOH. On chromosome 16q an inverted picture
was seen: in well- and intermediately differentiated DCIS, LOH
was found in 66% (26/39) of the cases and in 39% (12/31) of the
poorly differentiated DCIS. A total of 16 cases well-differentiated
DCIS showed LOH on chromosome 16q. Of these, eight cases
showed LOH for all markers informative on chromosome 16q, two
cases showed LOH of the whole chromosome and six cases
defined a smallest region of overlap between marker D16S2624
and D16S1320 (16q22.1–16q24.3). For both chromosome 16 and
17 the percentage of LOH in intermediately differentiated DCIS is
63%. In the four cases of well-differentiated DCIS with LOH on
chromosome 17, also LOH on chromosome 16 was present. In the
12 cases of poorly differentiated DCIS that show LOH on 16q,
83% also showed LOH on chromosome 17. In poorly differenti-
ated DCIS the number of loci involved in LOH per tumour is
significantly higher than in intermediately or well-differentiated
DCIS (Table 3).
Using marker D17S588 four cases of poorly differentiated
DCIS (BT1251, 1253, 1255 and 1265) showed a pattern which we
interpreted as allelic gain on chromosome 17q23. The same
tumour samples showed on other loci a complete loss of one allele
(Figure 3C) which indicates that these tumours exhibit a normal
pattern of LOH for other loci.
Oncogene amplification
Thirty-two cases were analysed using Southern blot hybridization
with six oncogene probes. C-erbB2/neu gene amplification was
found in 31% of the cases (10/32). C-myc, EGF-receptor, bek, flg
and MDM2 were not amplified in any of these DCIS. All cases
with oncogene amplification were of the poorly differentiated
type.
Comparative Genomic Hybridization
DNA from 15 cases of DCIS was subjected to CGH: ten were
poorly differentiated and five well-differentiated (Table 4). All 15
cases had multiple genetic aberrations affecting three to seven
different chromosomal regions per tumour. The most frequent
changes in the ten cases of poorly differentiated DCIS were gains
chromosome 8 chromosome 17
BT1204
BT1265
BT1255
BT1253
chromosome 1 chromosome 11
chromosome 16
445
290
265
Figure 4 (A) An illustration of the most common alterations found by CGH
in poorly differentiated DCIS, showing amplification of the q-arm of
chromosome 8, combined in two cases with deletion of the p-arm.
Amplification of two regions on chromosome 17q, 17q12 and 17q22–24 is a
predominant feature in poorly differentiated DCIS; in three cases there also
was a deletion on chromosome 17p. (B) An illustration of the most common
alterations detected by CGH in well differentiated DCIS, showing
amplification of 1q, combined with a deletion of chromosome 16q and an
amplification of 16p. In one case (BT1290) amplification of the 11q13 region
was found
Chromosome 8 Chromosome 17
Chromosome 16
Chromosome 1 Chromosome 11
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on 8q (4/10), 12q (3/10) and 17q (5/10) and losses on 16q (3/10)
and 17p (6/10). For well-differentiated DCIS the most frequent
alterations were gain on 1q (2/5) and loss on 16q (2/5) (Figure 4).
Concordance between LOH, Southern blot analysis and
CGH
In all cases we could confirm the deletions found by CGH with
LOH analysis. However, not all loci with LOH showed deletions
using CGH. An explanation can be that LOH frequently arises by
deletion of one allele followed by duplication of the remaining
allele as a result of mitotic recombination (Gupta et al, 1997). In
four poorly differentiated DCIS (BT1251, 1253, 1255 and 1265)
allelic imbalance for marker D17S588 was shown in the LOH
analysis (Figure 3C). By CGH, amplification at the 17q22-24
locus, which is the region in which D17S588 is located, was found.
In two out of four cases, co-amplification of 17q12, which
contains the c-erbB2/neu locus, was found (BT1255 and BT1265).
Copy gain of 17q12 found in three cases could always be
confirmed by amplification of c-erbB2/neu in Southern blot
analysis. In two cases (BT1251 and BT1253) only the 17q22-24
region was amplified (Table 4 and Figure 4) and also amplification
of the 17q12 alone was found (BT1224). By Southern blot analysis
no c-myc amplification was found in 32 cases of DCIS whereas
using CGH 8q amplification was found in 40% (4/10) of the
poorly differentiated DCIS (Table 4 and Figure 4). In all these
cases an increased signal intensity was seen for the entire q-arm of
the chromosome instead of a narrow amplification unit as is seen
for amplifications on 17q12 and 17q22-24. This suggests that there
is a duplication of the entire q-arm of one of the copies of chromo-
some 8 which is missed by Southern blotting because the reference
probe is also located on 8q. By Southern blot analysis no
amplification was found for MDM2 (located on 12q13). By CGH
we found amplification restricted to the q14–q15 region of
chromosome 12 in 30% of the poorly differentiated DCIS. The
EGF-receptor (7q26), bek (10q26) and flg (8p12) was never found
to be amplified, neither by Southern blot nor CGH.
DISCUSSION
The aim of this comprehensive study was to gain insight in the
locations and frequencies of regional chromosomal alterations in
different histological types of DCIS of the breast. Malignant
tumours arise through a cascade of genetic events involving onco-
genes and tumour suppressor genes resulting in a disruption of
normal cell growth regulation. Additional mutations and deletions
result in progression to invasion and metastasis. We have studied
whether there is a genetic explanation for the histologically
different types of DCIS.
In our study we found that LOH on chromosome 16q was found
in 66% of well- and intermediately differentiated DCIS and only in
39% of poorly differentiated DCIS. On 16q22.1, the E-cadherin
gene is located which has previously found to be inactivated in
invasive lobular carcinoma of the breast (Kanai et al, 1994; Berx et
al, 1995). Recently, we have shown that in lobular carcinoma in
situ (LCIS) E-cadherin is inactivated, whereas all cases of DCIS
express E-cadherin at the cell membrane (Vos et al, 1997).
Therefore another yet unidentified tumour suppressor gene is
target of LOH on 16q in DCIS (Cleton-Jansen et al, 1994; Tsuda et
al, 1994).
On chromosome 17, LOH was found in 70% of the poorly
differentiated DCIS cases, versus 17% in well-differentiated
DCIS. In 21% (15/72) (predominantly poorly differentiated DCIS)
LOH is found on the 17p-arm only. In most cases, p53 is thought to
be the target gene on 17p. Mutations in p53 are present in DCIS as
has been found by us (data not shown) and others (Chitemerere et
al, 1996; Munn et al, 1996).
We and others (Munn et al, 1996) found LOH in the 17q21
region in 21% and 67% of the DCIS cases respectively. LOH on
17q occurs in a large proportion of invasive breast cancers, both in
familial and sporadic cases. Chromosomal deletions on 17q21
point to a tumour suppressor gene close to the BRCA1 gene.
Inactivating point mutations in BRCA1 have only been found in
the germline in familial breast cancer, not as a de novo mutation in
sporadic breast cancer (Miki et al, 1994). Three other studies have
previously identified chromosomal loci with frequent allelic loss
in DCIS. In a study by Radford (Radford et al, 1995) the highest
percentage of LOH was found on chromosome 8p, 13q, 16q, 17p
and 17q. Aldaz (Aldaz et al, 1995) reported frequent LOH on 16q,
17p and 17q. In these studies DCIS was not histologically classi-
fied, but they confirm that alterations on chromosome 16 and 17
are early events in breast carcinogenesis. The only study (Fujii et
al, 1996) in which histological type and LOH were correlated
shows that loss on chromosome 16q and 17p were common in all
histologic types of DCIS, whereas loss on other chromosome arms
was uncommon in low-grade compared to intermediate- and high-
grade DCIS. As in our study the number of loci with LOH is
higher in poorly differentiated DCIS than in intermediately or
well-differentiated DCIS. However, in contrast to other findings
we were able to make a genetic distinction between well- and
poorly differentiated DCIS based on LOH and CGH profiles. It is
presently unclear whether breast cancer development via an inter-
mediately differentiated DCIS represents a distinct genetic
pathway. It is likely that some cases of intermediately differen-
tiated DCIS are derived from well-differentiated DCIS that show
an increase in cytonuclear pleomorphism as a result of the
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Figure 5 Proposed model for breast cancer initiation and progression. The
data to construe this model are from our own work and from the literature.
We hypothesize that there are several pathways for the development of
different types of breast cancer, which differ at the genetic level. A particular
genetic alteration is not a prerequisite for developing a certain tumour type,
but a strong correlation is found (e.g. LOH at 16q in well- and intermediately
differentiated DCIS and LOH at 17 in poorly differentiated DCIS)Genetic alterations in DCIS 1417
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accumulation of additional genetic alterations. During the
development of a histological classification for DCIS (Holland
et al, 1994) it has not been possible to classify all DCIS without
having a category of intermediately differentiated DCIS. When
more specific tumour suppressor genes are cloned in the future, it
will become clear whether there are specific genetic alterations in
intermediately differentiated DCIS.
Amplification of oncogenes is another important genetic alter-
ation in breast cancer. The most notable gain we found was 17q
amplification, for which at least two separate regions can be
discriminated, 17q12 and 17q22–q24. The oncogene that is ampli-
fied in the 17q12 region is c-erbB2/neu. The 17q22–q24 locus
harbours a yet unknown oncogene(s) which has been found to be
amplified in breast cancer cell lines and invasive breast cancer by
CGH (Kallioniemi et al, 1994).
In 10–15% of the invasive breast cancers amplification of the c-
myc gene on chromosome 8q24 is found (Varley et al, 1987; Berns
et al, 1992). We could not detect c-myc amplification in DCIS by
Southern blot analysis. Using CGH, gain of the entire q-arm of
chromosome 8 was found. We hypothesize that duplication of the
q-arm of chromosome 8 explains these results and conclude that
amplification of the c-myc gene occurs in a later stage of breast
cancer progression.
In conclusion, our findings support the evidence of different
genetic routes to develop a specific type of carcinoma in situ of the
breast. Figure 5 shows our proposal for a genetic model for the
development of DCIS and progression to invasive breast cancer
based on the data reported by us and others. Inactivation of E-
cadherin is the predominant event in LCIS and ILC. LOH on 16q
is found in the majority of well-differentiated DCIS and since E-
cadherin expression is always detectable in DCIS, there must be a
yet unknown tumour suppressor gene responsible for the develop-
ment of this type of DCIS. LOH and amplification of several
regions on chromosome 17 are predominant in poorly differenti-
ated DCIS, indicating that (multiple) aberrations on chromosome
17 are responsible for this subtype of DCIS. Inactivation of p53
leads to genomic instability including gene amplification
(Livingstone et al, 1992) and may explain the appearance of gene
amplification in combination with a high incidence of LOH on 17
in poorly differentiated DCIS. In most cases progression from
well-differentiated DCIS to Grade I invasive carcinoma and
poorly differentiated DCIS to Grade III invasive will take place. In
rare cases progression from well- to intermediately or intermedi-
ately to poorly differentiated DCIS is possible and associated with
genetic alterations on chromosome 17. In general, various alter-
ations on chromosome 16 and 17 are early and crucial steps in the
development of the different histological types of DCIS.
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